Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M. Mohr P, et al. Among authors: sunderkotter c. J Clin Oncol. 2015 Dec 1;33(34):4077-84. doi: 10.1200/JCO.2014.59.6932. Epub 2015 Oct 26. J Clin Oncol. 2015. PMID: 26503196 Clinical Trial.
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P; CNTO 95 Investigators. O'Day S, et al. Br J Cancer. 2011 Jul 26;105(3):346-52. doi: 10.1038/bjc.2011.183. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750555 Free PMC article. Clinical Trial.
Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, Luger TA, Sunderkötter C, Schiller M. Hüsken AC, et al. Among authors: sunderkotter c. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):71-8. doi: 10.1111/j.1468-3083.2011.04011.x. Epub 2011 Mar 9. J Eur Acad Dermatol Venereol. 2012. PMID: 22168776
Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma.
Mohr P, Birgersson U, Berking C, Henderson C, Trefzer U, Kemeny L, Sunderkötter C, Dirschka T, Motley R, Frohm-Nilsson M, Reinhold U, Loquai C, Braun R, Nyberg F, Paoli J. Mohr P, et al. Among authors: sunderkotter c. Skin Res Technol. 2013 May;19(2):75-83. doi: 10.1111/srt.12008. Epub 2013 Jan 27. Skin Res Technol. 2013. PMID: 23350668 Free article.
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version.
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Society of Dermatology. Pflugfelder A, et al. Among authors: sunderkotter c. J Dtsch Dermatol Ges. 2013 Jun;11(6):563-602. doi: 10.1111/ddg.12044. J Dtsch Dermatol Ges. 2013. PMID: 23721604 No abstract available.
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Dermatological Society; DermatologicCooperative Oncology Group. Pflugfelder A, et al. Among authors: sunderkotter c. J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126. doi: 10.1111/ddg.12113_suppl. J Dtsch Dermatol Ges. 2013. PMID: 24028775 English, German.
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C; German Dermatologic Cooperative Oncology Group (DeCOG). Leiter U, et al. Among authors: sunderkotter c. Lancet Oncol. 2016 Jun;17(6):757-767. doi: 10.1016/S1470-2045(16)00141-8. Epub 2016 May 5. Lancet Oncol. 2016. PMID: 27161539 Clinical Trial.
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C; Dermatologic Cooperative Oncology Group (DeCOG). Eigentler TK, et al. Among authors: sunderkotter c. Ann Oncol. 2016 Aug;27(8):1625-32. doi: 10.1093/annonc/mdw225. Epub 2016 Jun 10. Ann Oncol. 2016. PMID: 27287206 Free article. Clinical Trial.
301 results